Ewing Sarcoma Clinical Trials in Houston, Texas

6 studies are recruiting for ewing sarcoma in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

   Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastom…

   Stage

   Phase 1

   Ages

   0 to 25

   Site

   University of Texas MD Anderson Cancer Center ( Site 1007), Houston, Texas

   Locations

   71 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06395103 on ClinicalTrials.gov

2. Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

   This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).

   Stage

   Phase 1

   Ages

   12 to 85

   Site

   UT MD Anderson Cancer Center, Houston, Texas

   Locations

   37 in total

   Run by

   Inhibrx Biosciences, Inc

   See if you can join NCT03715933 on ClinicalTrials.gov

3. Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

   The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric participants with relapsed or refractory EWS.

   Stage

   Phase 1

   Ages

   2 and older

   Site

   University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   9 in total

   Run by

   Amgen

   See if you can join NCT07297979 on ClinicalTrials.gov

4. A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

   A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies

   Stage

   Phase 1

   Ages

   16 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   6 in total

   Run by

   SEED Therapeutics, Inc.

   See if you can join NCT07197554 on ClinicalTrials.gov

5. Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

   This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors. This is followed by the …

   Stage

   Phase 1

   Ages

   2 to 30

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   15 in total

   Run by

   Jazz Pharmaceuticals

   See if you can join NCT05734066 on ClinicalTrials.gov

6. HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

   The purpose of this study is to learn whether it is safe to give HER2-CAR T cells in combination with an immune checkpoint inhibitor drug (pembrolizumab or nivolumab), to learn what the side effects are, and to see whether this therapy might help patients with sarcoma. Another goal of this study is…

   Stage

   Phase 1

   Ages

   1 to 25

   Site

   Texas Children's Hospital, Houston, Texas

   Run by

   Baylor College of Medicine

   See if you can join NCT04995003 on ClinicalTrials.gov